Overview
- Veeva reported fiscal Q2 results that topped expectations with $928 million in revenue and about $416 million in non‑GAAP operating income and raised its full‑year revenue and EPS guidance.
- Subscription revenue rose in double digits to roughly $767 million and non‑GAAP operating margins stayed above 44 percent, showing growth without sacrificing profitability.
- Vault CRM delivered a record quarter with new commitments from major biopharma firms including Eli Lilly, Biogen and Regeneron, bringing adoption to 12 of the industry’s top 20 companies.
- Veeva Falcon, the company’s AI product, accelerated adoption during the quarter and management framed AI as the next major growth pillar for Veeva and its life‑science customers.
- The stock jumped about 20% in a single session after the results and nearly 20 sell‑side firms raised price targets, with management pointing to a November 5 investor day as the next key event to detail the AI strategy.